Unknown

Dataset Information

0

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.


ABSTRACT: Successful translation of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors has proved to be troublesome, mainly due to the complex tumor microenvironment promoting T cell dysfunction and antigen heterogeneity. Mesothelin (MSLN) has emerged as an attractive target for CAR T cell therapy of several solid malignancies, including ovarian cancer. To improve clinical response rates with MSLN-CAR T cells, a better understanding of the mechanisms impacting CAR T cell functionality in vitro is crucial. Here, we demonstrated superior cytolytic capacity of CD28-costimulated MSLN-CAR T cells (M28z) relative to 4-1BB-costimulated MSLN-CAR T cells (MBBz). Furthermore, CD28-costimulated MSLN CAR T cells displayed enhanced cytolytic capacity against tumor spheroids with heterogeneous MSLN expression compared to MBBz CAR T cells. In this study, we identified CAR-mediated trogocytosis as a potential impeding factor for successful MSLN-CAR T cell therapy due to fratricide killing and contributing to tumor antigen heterogeneity. Moreover, we link antigen-dependent upregulation of LAG-3 with reduced CAR T cell functionality. Taken together, our study highlights the therapeutic potential and bottlenecks of MSLN-CAR T cells, providing a rationale for combinatorial treatment strategies.

SUBMITTER: Schoutrop E 

PROVIDER: S-EPMC9313125 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9942695 | biostudies-literature
| S-EPMC6707377 | biostudies-literature
2019-03-27 | GSE126753 | GEO
| S-EPMC5963729 | biostudies-literature
| S-EPMC10652537 | biostudies-literature
| S-EPMC10749292 | biostudies-literature
| S-EPMC4006097 | biostudies-literature
| PRJNA523212 | ENA
| S-EPMC7541670 | biostudies-literature